Cochrane · systematic review · CD010982
Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation
Desborough, M, Estcourt, LJ, Doree, C, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
6
No studies
9
Included studies
NR
No studies 9 · 56.3%Ungraded 1 · 6.3%Very low 6 · 37.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Thrombopoietin mimetics versus placebo or standard care
Population: people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least 1 bleeding episode Thrombopoietin mimetics vs placebo or standard care | OR 0.4 [0.1, 1.62] | 1 study · 120 participants | Very low Downgraded: imprecision |
Number of participants with severe or life‐threatening bleeding Thrombopoietin mimetics vs placebo or standard care | OR 1.46 [0.06, 33.14] | 3 studies · 209 participants | Very low Downgraded: risk of bias, imprecision |
Number of days on which bleeding occurred ‐ not reported Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | NR | No studies |
Time from randomisation to first bleeding episode ‐ not reported Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | NR | No studies |
All‐cause mortality Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | 4 participants | Ungraded |
Number of platelet transfusions Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | 1 study · 120 participants | Very low Downgraded: imprecision |
Thromboembolic events Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | 2 studies · 209 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life ‐ not reported Thrombopoietin mimetics vs placebo or standard care | no estimate extracted | NR | No studies |
Platelet‐poor plasma
Population: people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least 1 bleeding episode | OR 16 [1.32, 194.62] | 1 study · 18 participants | Very low Downgraded: risk of bias |
Number of participants with severe or life‐threatening bleeding | OR 4 [0.56, 28.4] | 1 study · 18 participants | Very low Downgraded: risk of bias |
Number of days on which bleeding occurred ‐ not reported | no estimate extracted | NR | No studies |
Time from randomisation to first bleeding episode ‐ not reported | no estimate extracted | NR | No studies |
Number of platelet transfusions ‐ not reported | no estimate extracted | NR | No studies |
All‐cause mortality ‐ not reported | no estimate extracted | NR | No studies |
Thromboembolic events ‐ not reported | no estimate extracted | NR | No studies |
Quality of life ‐ not reported | no estimate extracted | NR | No studies |